Status

Recruiting

Lead Investigator

Dr Gordon Moran

Consultant Gastroenterologist

Nottingham University Hospitals NHS Trust

 

 

What is the study about?

There are plenty of studies showing that aminosalicylates (5-ASA or mesalazine) are very useful drugs in the treatment of Ulcerative colitis. Equally, there are plenty of studies showing that they are NOT useful in the treatment of Crohn’s disease. In fact, they are little more than a placebo in Crohn’s disease. To this effect, the British Society of Gastroenterology does not suggest using 5ASAs to treat CD. However, a large proportion of patients with Crohn’s disease are still prescribed 5ASAs, even after other medication (like azathioprine or biologics) has been added to help control their symptoms.

This clinical trial will aim to definitively prove that 5ASAs have no role in the management of CD, and it is indeed safe to stop these medications when CD is in remission (i.e. currently not flaring). The study aims to show that stopping or continuing 5ASAs will not have any effect on disease flares and complications related to CD. 

Who can take part in the study?

Patients over 18 with Crohn’s Disease (CD) that is in remission and are currently taking a type of medication known as an aminosalicylate (5-ASA or mesalazine).

What is being tested in the study?

Discontinuation of current 5-ASA treatment

What is this being compared to?

Continuation of current 5-ASA treatment

What are we trying to find out?

Whether stopping 5ASAs will have any effect on disease flares and complications related to Crohn's Disease. 

How many patients do we need?

Up to 1580 patients

Funder

Alimentiv obtained academic grants which are used to provide funding for this study

Useful links